Benitec Biopharma Ltd (BNTC)

[georgejjl]

Expect efficacy at the current cohort 3 dose level

Per Dr. David Suhy:

Transduction levels roughly consistent with pre-clinical studies: QPCR analysis:
• Subject 1 cohort 1 (4e10 vg/kg): 0.02 copies TT-034 per cell (average)
• Subject 2 cohort 1 (4e10 vg/kg): 0.01 copies TT-034 per cell (average)
• Subject 1 cohort 2 (1.25e11 vg/kg): 0.48 copies TT-034 per cell (average)

If consistent with pre-clinical studies, cohort 3 may have significantly higher percentage of DNA transduction

****************************************************************************************

The human transduction of TT-034 in human subjects has been consistent with the animal studies. therefore expect efficacy at the current cohort 3 dose level, which is 3.16 times greater than the dose given for cohort 2 and 10 times greater than the dose given to the first dose cohort.

Notice that for the second dose cohort on there were 0.48 copies of TT-034 transduced per liver cell. Now think about this: the third dose cohorts dose is 3.16 times greater than the second dose cohort. You do the math.

http://blt.live.hqi.com.au/IRM/Company/ShowPage.aspx/PDFs/1540-10000000/BENITECPRESENTSATAGCTSCONFERENCE

Good luck and GOD bless,

George